Medicinal and edible medicine composition as well as preparation method and application thereof

By improving the formula for children's Qixing Tea, adding malt, chrysanthemum, yam and other medicinal and food homologous raw materials, we developed a medicinal and food homologous pharmaceutical composition, which solved the problem that the existing pediatric seven-star tea cannot prevent pediatric food accumulation and achieved higher Safe and more consistent with the modern diet structure, and improve productivity and safety.

CN118903338APending Publication Date: 2024-11-08GUANGZHOU WANGLAOJI PHARM CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410714920.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-03
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing pediatric Qixing Tea Granules cannot be taken for a long time and cannot prevent pediatric food stasis. The prescription does not conform to the dietary structure of modern people, resulting in limited efficacy.

Method used

Improve the formula for children's Qixing Tea, add malt, chrysanthemum, yam, light bamboo leaves and licorice, combine modern preparation technology and production technology to develop a medicinal and food homologous pharmaceutical composition, and prepare it into extracts, tablets, capsules, and granules. Or pills, improve production efficiency and safety by adjusting the feed order, extraction and concentration process and drying process.

Benefits of technology

It provides a long-term edible medicinal and food homologous pharmaceutical composition, which has higher safety and better preventive effect of pediatric stasis. It is suitable for modern people's dietary structure, and the production process significantly improves efficiency and reduces costs. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903338A_ABST
    Figure CN118903338A_ABST
Patent Text Reader

Abstract

The invention discloses a medicinal and edible medicine composition as well as a preparation method and application thereof. The medicinal and edible medicine composition is prepared from the following raw materials: malt, chrysanthemum, hawthorn, coix seed, Chinese yam, lophatherum gracile and liquorice. The medicine composition with homology of medicine and food is more suitable for dyspepsia caused by the dietary structure of modern people, is composed of the raw medicinal materials with homology of medicine and food in the whole formula, has higher safety, can be eaten for a long time, and can be used for daily health care and prevention of dyspepsia diseases. Besides, by improving extraction equipment, a feeding sequence, an extraction and concentration process, a drying process and storage conditions, the production process suitable for the invention is developed, and compared with the existing process, the production efficiency is remarkably improved, and the production cost is greatly reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of traditional Chinese medicine compositions, and in particular relates to a medicine and food homologous medicine composition and a preparation method and application thereof. Background Art

[0002] With the improvement of the quality of life, the problem of improper feeding of children has become increasingly prominent. Food accumulation has become a common digestive tract disease in children, which not only affects children's nutrient absorption, but also causes serious troubles to children's sleep, greatly affecting their physical development. Food accumulation is a common digestive tract symptom in young children, with a high incidence and repeated attacks, which seriously affects the growth and development of young children.

[0003] Seven-star tea for children is one of the national essential medicines. It is made from coix seeds, rice sprouts, hawthorn, bamboo leaves, Uncaria rhynchophylla, cicada molt and licorice. It has the effects of appetizing, eliminating stagnation, clearing away heat and calming the nerves. Current studies have found that seven-star tea has a good effect on children with food accumulation. However, the seven-star tea granules for children on the market are all medicines. Although they have a certain degree of safety, they cannot be taken for a long time and cannot prevent the symptoms.

[0004] Therefore, there is an urgent need to develop a medicine-food homologous drug composition that can be used to prevent food accumulation in children. Summary of the invention

[0005] In order to solve the problem of preventing food accumulation in children, the present invention provides a medicine-food homologous drug composition and its preparation method and application based on the prescription of children's seven-star tea by improving the original prescription without changing the efficacy and indications, providing a new choice for the prevention and improvement of food accumulation in children. Specifically, the present invention includes the following contents.

[0006] The first aspect of the present invention provides a medicine-food homologous medicine composition, which is prepared from raw materials including malt, chrysanthemum, hawthorn, coix seed, yam, loquat leaf and liquorice.

[0007] In certain embodiments, the edible and medicinal composition according to the present invention comprises: 60-100 parts by weight of malt, 20-60 parts by weight of chrysanthemum, 20-60 parts by weight of hawthorn, 20-60 parts by weight of coix seed, 5-45 parts by weight of yam, 20-60 parts by weight of loquat leaf and 1-30 parts by weight of liquorice.

[0008] In certain embodiments, the medicine-food homologous pharmaceutical composition according to the present invention has a formulation type including extracts, tablets, capsules, granules, pills or powders.

[0009] The second aspect of the present invention provides a method for preparing a medicine-food homologous pharmaceutical composition, which comprises the following steps:

[0010] (1) Take bamboo leaves, chrysanthemum, malt, liquorice, hawthorn, Chinese yam and coix seed, add them in the above order, add water to boil, filter, concentrate the combined filtrate for the first time, centrifuge, and concentrate the centrifuge for the second time to obtain a concentrated paste;

[0011] (2) preparing fine powder auxiliary materials;

[0012] (3) The concentrated paste is mixed with the fine powder auxiliary material, dried at 50-70° C. (preferably 51-69° C., further preferably 52-68° C., more preferably 53-67° C., more preferably 54-66° C., more preferably 55-65° C., for example 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65° C.), and granulated.

[0013] In certain embodiments, according to the preparation method of the present invention, step (2) comprises: grinding at least one carbohydrate auxiliary material to obtain fine powder and then passing it through a 80-120 mesh sieve.

[0014] In certain embodiments, according to the preparation method of the present invention, the decocting is performed twice, with 8-12 times the amount of water added in the first decocting and 4-8 times the amount of water added in the second decocting, each time for 0.5-2 hours, and the decoctions are combined.

[0015] In certain embodiments, according to the preparation method of the present invention, at 55-60°C, for example 55, 56, 57, 58, 59, 60°C, the first concentration is to a relative density of 1.02-1.05, for example 1.02, 1.025, 1.03, 1.035, 1.04, 1.045, 1.05, and the second concentration is to a relative density of 1.28-1.35, for example 1.28, 1.29, 1.30, 1.31, 1.32, 1.33, 1.34, 1.35.

[0016] In certain embodiments, according to the preparation method of the present invention, wherein the carbohydrate auxiliary material comprises white sugar and / or edible glucose, the step of preparing the fine powder auxiliary material in step (2) further comprises a step of mixing with prebiotics.

[0017] In certain embodiments, according to the preparation method of the present invention, an extraction tank is used to carry out the feeding, extraction and concentration processes, wherein the extraction tank comprises an extraction liquid flow exchange device.

[0018] The third aspect of the present invention provides use of the medicine-food homologous medicinal composition of the present invention in the preparation of stomachic and digestive medicines or health foods.

[0019] In certain embodiments, according to the use of the present invention, the stomachic and digestive medicine or health food is used for stomachic and digestive function, clearing away heat and stimulating appetite, or preventing food accumulation in children.

[0020] Compared with the original formula of Children's Seven-star Tea, the medicine and food pharmaceutical composition of the present invention has improved raw material composition, added medicine and food raw materials such as yam, chrysanthemum, malt and prebiotic stachyose, and removed the medicinal flavors of rice sprouts, Uncaria rhynchophylla and cicada shells, which is more in line with food accumulation disease caused by the dietary structure of modern people. The whole formula is composed of medicine and food raw materials, has higher safety, can be eaten for a long time, and can be used for daily health care and prevention of food accumulation diseases.

[0021] In addition, in terms of preparation technology, since the prescription of the present invention adds starch-rich raw medicinal materials such as yam, the original production process is no longer applicable. The present invention develops a production process suitable for the present invention by improving the extraction equipment, feeding sequence, extraction and concentration process, drying process and storage conditions. Compared with the original process, the production efficiency is significantly improved and the production cost is greatly reduced. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 The flowchart of the preparation process of the edible and medicinal composition of the present invention is shown. DETAILED DESCRIPTION

[0023] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0024] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that the upper and lower limits of the scope and each intermediate value therebetween are specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0025] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as commonly understood by those skilled in the art to which the invention belongs. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials related to the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0026] Medicine and food homologous drug composition

[0027] One aspect of the present invention provides a "medicine and food composition (sometimes also referred to as "Qingqingle" herein)", which improves the formula of Children's Seven-Star Tea based on the theory of traditional Chinese medicine, uses Chinese medicinal materials that are both medicine and food to replace non-medicine and food medicinal materials in the formula, and develops a medicine and food composition with the function of clearing away heat and eliminating accumulation through modern preparation technology and production process.

[0028] In Xiaoer Qixing Tea, hawthorn and rice sprouts are the main drugs. Hawthorn can help digestion, invigorate the stomach and soothe the liver, and is good at digesting meat. Rice sprouts can help digestion, invigorate the stomach and eliminate restlessness, and are good at digesting rice and flour. The ministerial drugs are coix seed and light bamboo leaf. Coix seed can promote diuresis, eliminate dampness, strengthen the kidney and strengthen the spleen, and light bamboo leaf can promote urination and clear the heart. The auxiliary drugs are Uncaria rhynchophylla and cicada shell. Uncaria rhynchophylla can soothe the liver and relieve wind, and cicada shell is pungent, cool and penetrating. The messenger drug licorice can nourish the liver and replenish qi, clear away heat and detoxify, and harmonize various drugs. Compared with Xiaoer Qixing Tea, in the present invention, the Chinese medicine pair coix seed and yam is the main drug, the yam and malt medicine pair is the ministerial drug, chrysanthemum and light bamboo leaf are the adjuvant drugs, and licorice is the messenger drug. Among them, yam and coix seed form a medicine pair combination, which can nourish the spleen and stomach, promote fluid and benefit the lungs, and nourish the kidney and astringe the essence. The combination of the two can improve the spleen-strengthening effect. In the Chinese medicine combination of malt and hawthorn, hawthorn is good at eliminating meat stagnation. On the basis of being good at eliminating pasta, malt also has the function of promoting qi and removing stagnation, and eliminating milk stagnation. Compared with the original formula of Children's Seven Star Tea, hawthorn and malt are good at eliminating food stagnation caused by rice, noodles, meat, and dairy products. Its digestive characteristics are more in line with the food stagnation caused by the dietary structure of modern people. Replacing Uncaria and cicada shells with chrysanthemum still has the effect of soothing the liver and clearing heat, but the medicinal properties are more peaceful. In addition, adding natural sweetness sources to neutralize the sour taste of hawthorn and add new flavors. Light bamboo leaves clear the heart and relieve troubles, and licorice is added to harmonize the medicines. The whole recipe uses raw materials of medicinal and edible origin, which are mild in nature and have the effects of strengthening the spleen, digesting food, and clearing heat, making it more suitable for daily use. In addition, on the basis of the formula of medicine and food of the same origin, the natural prebiotic stachyose is added in combination with modern nutritional theory. It can have a very obvious proliferation effect on the beneficial bacteria such as bifidobacteria and lactobacilli in the human gastrointestinal tract, and can quickly improve the internal environment of the human digestive tract, regulate the balance of microecological bacteria, improve digestion and inhibit diarrhea.

[0029] In a preferred embodiment, the medicine and food composition of the present invention comprises 60-100 parts by weight (preferably 65-95 parts by weight, preferably 70-90 parts by weight, more preferably 75-85 parts by weight, for example 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 parts by weight) of malt, 20-60 parts by weight (preferably 25-55 parts by weight, preferably 30-50 parts by weight, more preferably 35-4 5 parts by weight, for example 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 parts by weight) of chrysanthemum, 20-60 parts by weight (preferably 25-55 parts by weight, also preferably 30-50 parts by weight, more preferably 35-45 parts by weight, for example 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 parts by weight) of hawthorn, 20-60 parts by weight (preferably 25-55 parts by weight, also preferably 30-50 parts by weight, more preferably 35-45 parts by weight, for example 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 parts by weight) of 30-50 weight parts, more preferably 35-45 weight parts, for example 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 weight parts) of coix seeds, 5-45 weight parts (preferably 10-40 weight parts, further preferably 15-35 weight parts, more preferably 20-30 weight parts, for example 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 weight parts) of yam, 20-60 weight parts (preferably 10-40 weight parts, further preferably 15-35 weight parts, more preferably 20-30 weight parts, for example 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 weight parts) of parts by weight (preferably 25-55 parts by weight, also preferably 30-50 parts by weight, more preferably 35-45 parts by weight, for example 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 parts by weight) of Leptospermum officinale and 1-30 parts by weight (preferably 2-25 parts by weight, also preferably 4-20 parts by weight, more preferably 6-15 parts by weight, for example 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 parts by weight) of Licorice.

[0030] The medicine-food homologous pharmaceutical composition of the present invention further comprises 0.1-5 parts by weight of prebiotics, preferably 0.5-2 parts by weight, and preferably 0.8-1.8 parts by weight, such as 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8 parts by weight of prebiotics and 5-30 parts by weight of carbohydrate adjuvants, preferably 10-30 parts by weight, and preferably 10-20 parts by weight, such as 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 parts by weight of carbohydrate adjuvants. The carbohydrate adjuvants in the present invention include but are not limited to white sugar and / or edible glucose, and the prebiotics include but are not limited to stachyose.

[0031] The preparation type of the medicine-food homologous pharmaceutical composition is not particularly limited, and can be an extract, granules, tablets, capsules, powders or pills. In a preferred embodiment, the preparation type of the medicine-food homologous pharmaceutical composition of the present invention is a granule.

[0032] Preparation method

[0033] One aspect of the present invention provides a method for preparing a medicinal composition of medicine and food. The present invention has found through research that multiple problems occur during the use of conventional extraction: the texture of the medicinal materials varies greatly, and the light-textured drugs (light bamboo leaves, chrysanthemum) float on the surface of the extract, resulting in incomplete extraction; the heavy-textured drugs (yam, coix seed) are rich in starch and are easy to sink to the bottom and directly contact the heating part of the extraction tank to gelatinize or block the liquid outlet. The present invention effectively solves the above problems by adjusting the feeding sequence, preferably feeding in sequence according to the weight of the drug texture. Specifically, the feeding sequence is adjusted according to the weight of the drug to light bamboo leaves, chrysanthemum, malt, licorice, hawthorn, yam and coix seed, and the heavy-textured drugs are used to press the light-textured drugs to reduce floating. At the same time, the light bamboo leaves can isolate the yam and coix seed from contact with the bottom of the container to avoid gelatinization. In addition, the present invention improves the extraction tank, adds a device for the flow exchange of the extract, accelerates the outflow of effective substances and reduces the deposition of starch macromolecules, improves the extraction efficiency, and reduces the extraction time and energy consumption. Preferably, the device for liquid flow exchange is a circulation pump, which may be an internal circulation pump or an external circulation pump, and is not particularly limited thereto. The circulation pump may be disposed at the bottom, middle or top of the extraction tank.

[0034] Related research on the concentration stage of the preparation process of the present invention found that because many medicinal materials are rich in macromolecular substances such as starch, their extracts cannot be directly concentrated, and starch is not an effective ingredient and is easy to agglomerate in the granulation process, affecting granulation. The inventors compared the removal effects of processes such as standing, alcohol precipitation, centrifugation and pressurized filtration on starch in the extract in parallel. The results showed that compared with standing, alcohol precipitation and pressurized filtration, centrifugation has the highest efficiency and lower cost in effectively removing macromolecular substances, and can retain effective substances to the maximum extent compared with alcohol precipitation.

[0035] During the extract preservation stage of the preparation process of the present invention, it was found that the prepared extract is rich in carbohydrates and is prone to bacterial growth and mold. After testing various storage conditions, it was finally determined that the best storage condition is refrigeration.

[0036] The present invention further explores the added auxiliary materials, and comparative studies have found that the fineness of sugar particles has a greater impact on the adsorption of the extract, among which the subdivision has a minimum adsorption effect on the extract. This can be achieved by controlling the particle size of the fine powder auxiliary materials. The inventors have found that the particle size should not be too large or too small. Too large or too small will affect the molding of the preparation to varying degrees and cannot be made into medicine. In a preferred embodiment, the appropriate particle size suitable for the preparation preparation method of the present invention is obtained by controlling the number of sieving.

[0037] The present invention further optimizes the granulation process. Considering that the sample is rich in sugars and starch and is prone to agglomeration when exposed to high temperatures, the inventor optimizes the drying temperature to inhibit the growth of microorganisms. The results show that when the sample is dried within 55°C-65°C, the adhesion between particles is significantly reduced, the granulation effect is the best, and sterilization above 55°C can effectively inhibit the growth of microorganisms. In addition, stability studies have shown that when the moisture content is dried to the range of 2-3%, the internal properties, active ingredient content and microbial inspection indicators during the shelf life are all qualified.

[0038] In a preferred embodiment, the preparation steps of the present invention include:

[0039] (1) Take the weight portions of bamboo leaves, chrysanthemum, malt, liquorice, hawthorn, Chinese yam and coix seed as described herein, add them in the above order, add water to boil, filter, and concentrate the combined filtrate for the first time,

[0040] Centrifuge, and concentrate the centrifuge for the second time to obtain a concentrated paste;

[0041] (2) preparing fine powder auxiliary materials;

[0042] (3) The concentrated paste is mixed with the fine powder auxiliary material, dried at 50-70° C. to make the moisture content less than 3%, preferably less than 2%, more preferably less than 1%, and even more preferably less than 0.1%, and granulated.

[0043] Preferably, the time of the two extraction processes is 0.5-2 h, preferably 0.8-1.5 h, preferably 0.8-1.2 h, for example 0.8, 0.9, 1.0, 1.1, 1.2 h.

[0044] After the two extractions, the first concentration is performed, and the extract after concentration has a temperature of 1-10 degrees Baume, preferably 2-8 degrees Baume, and more preferably 4-8 degrees Baume, such as 4, 5, 6, 7, 8 degrees Baume. The concentration tank at this time can adopt a double-effect concentration tank known in the art, and the concentration temperature is not particularly limited, but the temperature is preferably 70-90°C, such as 70, 75, 80, 85, 90°C.

[0045] In the present invention, the concentrate after the first concentration can be placed for a period of time until the temperature cools to 55-65°C. Then centrifugation is performed, and the centrifugation can be performed using a tubular centrifuge. The centrifugation parameters are not particularly limited and can be adjusted as needed. After the centrifugation is completed, a second concentration is performed, and the extract after the second concentration is 30-50 degrees Baume, preferably 32-40 degrees Baume, and also preferably 32-38 degrees Baume, for example, 32, 33, 34, 35, 36, 37, 38 degrees Baume. At this time, the concentration tank can adopt a single-effect concentration tank known in the art, and the concentration temperature is not particularly limited, but a temperature of 45-55°C is preferred, for example, it can be 45, 50, 55°C.

[0046] Example 1

[0047] This example exemplifies a medicine-food homologous pharmaceutical composition and a preparation method thereof.

[0048] 1. The prescription of Qingqingle is shown in Table 1 below.

[0049] Table 1 Qingqingle prescription

[0050] Malt 82.6kg Chrysanthemum 41.3kg Hawthorn 41.3kg Job's tears 41.3kg Yam 25.2kg Light bamboo leaves 41.3kg Licorice 8.4kg Stachyose 1.52kg White sugar 10.88kg

[0051] 2. General preparation process

[0052] (1) Extraction: Add the ingredients (bamboo leaves, chrysanthemum, malt, liquorice, hawthorn, yam and coix seed) in order of their weight, add water and boil twice, add 10 times the amount of water for the first time and 6 times the amount of water for the second time, each time for 1 hour, filter the decoction, combine, and concentrate to a relative density of 1.02-1.05 (measured at 55-60°C), cool to room temperature, centrifuge, collect the centrifuge, and concentrate to a relative density of 1.28-1.35 (measured at 55-60°C) to obtain a concentrated paste, which is stored in a refrigerator.

[0053] (2) Preparation of auxiliary materials: White sugar and edible glucose were mixed and ground into fine powder. After passing through a 100-mesh sieve, 10.88 kg was weighed and mixed with 1.52 kg of prebiotic stachyose to obtain auxiliary material sugar powder.

[0054] (3) Granulation: The above-mentioned powdered sugar and 4.23 kg of extract were granulated. The extract was added twice, and each time was mixed using a high-efficiency wet granulator, and the mixing time was 7 seconds. The granules were granulated using a swing granulator with a 14-mesh screen, and dried in an oven at 55-65° C. until the moisture content was less than 2-3%, and sieved to obtain granules in the range of 14 to 40 mesh.

[0055] (4) Quality inspection: Testing the color, state, smell, taste, moisture, heavy metals, harmful elements and microorganisms of the finished product.

[0056] (5) Inner packaging: Use granule packaging equipment to inner package the qualified finished products, 6g / bag.

[0057] (6) Outer packaging: Label the product and pack it in boxes.

[0058] Example 2

[0059] This example shows a medicine-food homologous drug composition and a preparation method thereof.

[0060] 1. Materials and Equipment

[0061] 1.1 Prepare raw materials: 49.33kg malt, 24.67kg hawthorn, 24.67kg coix seed, 24.67kg chrysanthemum, 24.67kg loblolly leaf, 15kg yam and 5kg licorice.

[0062] 1.2 Prepare the circulation extraction tank

[0063] 2. Preparation process

[0064] Extraction: Select and rinse the raw medicinal materials, add them in order according to the weight of the drug (light bamboo leaves, chrysanthemum, malt, licorice, hawthorn, yam and coix seed in order), add water and boil twice, add 1680L RO water for the first time, add 1008L RO water for the second time, each time for 1 hour, filter the decoction through a 200-mesh filter, combine, concentrate to a relative density of 1.025, about 4Be (two-effect concentration tank, temperature 90℃), cool to 60℃, centrifuge, collect the centrifuge, concentrate to a relative density of 1.28-1.35, 32-38Be (single-effect concentration tank, temperature 50℃), and obtain a concentrated paste, which is stored in a refrigerator. The circulating pump is closed during extraction.

[0065] The remaining steps are the same as those in Example 1. Figure 1 shown.

[0066] Example 3

[0067] This example shows a medicine-food homologous drug composition and a preparation method thereof.

[0068] 1. Materials and Equipment

[0069] 1.1 Prepare raw materials: 49.33kg malt, 24.67kg hawthorn, 24.67kg coix seed, 24.67kg chrysanthemum, 24.67kg loblolly leaf, 15kg yam and 5kg licorice.

[0070] 1.2 Prepare the circulation extraction tank

[0071] 2. Preparation process

[0072] Extraction: Select and rinse the raw medicinal materials, add them in order according to the weight of the drug (light bamboo leaves, chrysanthemums, malt, licorice, hawthorn, yam and coix seeds in order), add water and boil twice, add 1680L RO water for the first time, add 1008L RO water for the second time, each time for 1 hour, filter the decoction through a 200-mesh filter, combine, and concentrate to a relative density of 1.025 and about 4Be (two-effect concentration tank, temperature 90°C), cool to 60°C, centrifuge, collect the centrifuge, and concentrate to a relative density of 1.28-1.35 and 32-38Be (single-effect concentration tank, temperature 50°C), and then obtain a concentrated paste, which is stored in a refrigerator. The circulating pump is turned on during extraction.

[0073] The remaining steps are the same as those in Example 1.

[0074] Comparative Example 1

[0075] The following is a method for preparing the edible and medicinal composition.

[0076] 1. Materials and Equipment

[0077] 1.1 Prepare raw materials: 49.33kg malt, 24.67kg hawthorn, 24.67kg coix seed, 24.67kg chrysanthemum, 24.67kg loblolly leaf, 15kg yam and 5kg licorice.

[0078] 1.2 Prepare the circulation extraction tank

[0079] 2. Preparation process

[0080] Extraction: clean and rinse the raw medicinal materials, mix and feed (randomly mix and feed in a manner other than the embodiment), add water and boil twice, add 1680L RO water for the first time, add 1008L RO water for the second time, each time for 1 hour, filter the decoction through a 200-mesh filter, combine, concentrate to a relative density of 1.025, about 4Be (two-effect concentration tank, temperature 90°C), cool to 60°C, centrifuge, collect the centrifuge, concentrate to a relative density of 1.28-1.35, 32-38Be (single-effect concentration tank, temperature 50°C), and obtain a concentrated paste, which is stored in a refrigerator. The circulating pump is closed during extraction.

[0081] The remaining steps are the same as those in Example 1.

[0082] The comparison of the schemes of Comparative Example 1 and Examples 2 and 3 is shown in Table 2:

[0083] Table 2 Comparison of the schemes of comparative example 1 and embodiments 2 and 3

[0084]

[0085] 3. Experimental results

[0086] The results of Comparative Example 1 and Examples 2 and 3 are compared as shown in Table 3:

[0087] Table 3 Comparison of the results of comparative example 1 with examples 2 and 3

[0088]

[0089]

[0090] The extract of comparative example 1 was dark green, indicating abnormal extraction. Analysis of the cause: it may be that the bamboo leaves and chrysanthemum floated on the surface of the extract or adhered to the wall of the tank, and were directly heated by steam, resulting in excessive extraction of pigments in the bamboo leaves or chrysanthemum medicinal materials.

[0091] 4. Summary

[0092] Each step of the trial production process of Examples 2 and 3 was strictly carried out according to the requirements, the feeding speed was fast, and there was no blockage. Results: The total solids of the extract were 52.0%, and the yield was 10.1% (Example 2); the total solids of the extract were 53.0%, and the yield was 12.3% (Example 3). The extracts of Examples 2 and 3 were diluted according to the final product amount and were brown-yellow in color, normal, and the pH value was 4.49. The microbial indicators (total colony count, coliform group, mold and yeast) all met the requirements.

[0093] After the test, the following points are summarized in the extraction process:

[0094] a. Feeding: Different batches of bamboo leaves contain different impurities, so you need to wash the bamboo leaves to remove the impurities. The order of feeding is bamboo leaves, chrysanthemum, malt, licorice, hawthorn, yam and coix seed.

[0095] b. Decoction: The amount of water added during extraction should be as accurate as possible; use hot water for extraction, or use indirect steam heating. Direct steam heating is not used in the entire process. The herbs can be heated to boiling and then kept warm. Turning on the circulation pump in the middle of decoction can increase the extraction yield, speed up the feeding speed, and shorten the total extraction time.

[0096] c. Concentration: It is more appropriate to concentrate the extract to 4-5 degrees Baume (85-90℃).

[0097] d. Cooling: The extract must be cooled to room temperature (10-30°C) before centrifugation.

[0098] e. Concentrated paste: It is more appropriate to concentrate to 37-38 degrees Baume (50-60℃).

[0099] Comparative Example 2

[0100] The following shows the process test data of sugar powder particle size in the preparation method of the medicine-food homologous drug composition, and the particle size of the fine powder auxiliary materials is controlled to be different, as shown in the following table:

[0101] Table 4

[0102]

[0103] Note: Head powder refers to powder with too large particle size; tail powder refers to powder with too small particle size.

[0104] The test on the particle size of powdered sugar shows that when medium powder with a sieve size below 80 mesh is used in the preparation, its adsorption capacity is poor, more tail powder is produced, the yield rate is low, and the powder paste required for the preparation is relatively large. When fine powder with a sieve size above 120 mesh is used in the preparation, more lumps are formed after drying, the rate of head powder is high, the drying time required is long, and the yield rate is low. In summary, the use of fine powder has the highest yield rate.

[0105] Application Examples

[0106] 1. Experimental materials:

[0107] 1. Test drugs: 1, Qingqingle extract, provided by Guangzhou Wanglaoji Pharmaceutical Co., Ltd. (batch number 1911606). Positive control Xiaoer Qixing Tea extract was provided by Guangzhou Wanglaoji Pharmaceutical Co., Ltd. (batch number 2001433).

[0108] 2. Animals: 3-4 weeks old, SPF grade SD rats, 140-160 g, half male and half female, purchased from Guangdong Experimental Animal Center.

[0109] 3. Reagents and consumables are shown in Table 5.

[0110] Table 5 List of reagents and consumables

[0111]

[0112]

[0113] 4. The main instruments are shown in Table 6.

[0114] Table 6 List of main instruments

[0115]

[0116] 2. Experimental Methods

[0117] (1) Experimental model groups: blank control group (A), model group (B), Qingqingle high-dose group (C), Qingqingle medium-dose group (D), Qingqingle low-dose group (E) and Xiaoer Qixing Tea control group (F), 8 rats in each group, 4 males and 4 females.

[0118] (2) Establishment of experimental model: Except for the blank control group which was fed with normal maintenance feed, the other groups (B, C, D, E, and F) were given high-calorie feed (chicken breast, fresh eggs, corn flour, animal fat, sugar, and milk powder in a ratio of 1:1 between corn flour and other materials, extruded into strips, heated at 105°C for 20 min, cut into sections, and dried until the moisture content was less than 5%). The experimental model was successfully established on the 25th day of the experiment. The model group showed symptoms such as loss of appetite, abdominal distension, constipation, increased rectal temperature, and slow weight gain, which were significantly different from the normal control group.

[0119] (3) Dosage method: After successful modeling, each group of animals was treated daily for 14 consecutive days as follows: Group C was gavaged with 24 g / kg Qingqingle extract (equivalent to 72.6 g of crude drug, 4 times the human dose); Group D was gavaged with 12 g / kg Qingqingle extract (equivalent to 36.3 g of crude drug, 2 times the human dose); Group E was gavaged with 6 g / kg Qingqingle extract (equivalent to 18.2 g of crude drug, 0.5 times the human dose); Group F was gavaged with 12 g / kg Xiaoer Qixingcha extract (equivalent to 36.3 g of crude drug, 1 times the human dose); and Groups A and B were gavaged with an equal volume of normal saline.

[0120] (4) Detection method: The body weight, rectal temperature, and food intake of rats were measured on days 1, 7, and 14. The rats were fasted for 12 h on the 14th day of administration and euthanized 2 h after administration. The stomach organs were dissected and the gastric juice was collected to measure the pH value and pepsin activity of the gastric juice.

[0121] (5) Pepsin activity detection: The pepsin activity determination refers to the 2016 version of the National Standard of the People's Republic of China (GB 1886.174-2016). The specific operation is as follows: at the optimal pH and optimal temperature, take 1.00 mL of preheated enzyme solution and mix it with 1.00 mL of preheated 1% bovine hemoglobin solution. After shaking for 10 minutes, 2.00 mL of trichloroacetic acid solution is added to the system to terminate the reaction. The reaction solution is centrifuged at 4°C and 20,000×g for 5 minutes, and the supernatant is filtered with a 0.22μm microporous filter membrane. 5 mL of sodium carbonate solution is added to 1.00 mL of supernatant to adjust the pH of the system. After mixing, 1.00 mL of Folin phenol reagent is added again. After incubation at 40°C for 20 minutes, the absorbance value is measured at 680 nm. The protease activity is 1 g or 1 mL of enzyme solution under certain conditions. Under 1 minute, 1 μg of tyrosine is produced, which is 1 enzyme activity unit, and the unit is U.

[0122] (6) Statistical method: The data of each group are expressed as mean ± variance The data were analyzed statistically, and the inter-group data were analyzed by variance analysis, with p < 0.05 considered statistically significant.

[0123] 3. Experimental Results

[0124] The experimental results are shown in Tables 7-10.

[0125] Table 7 Effect on food intake of young rats with food indigestion

[0126]

[0127] Note: Compared with the blank control group, **P<0.01, compared with the model group, ##P<0.01.

[0128] On the first day, the food intake of the model group, Qingqingle high, medium, low dose groups and the pediatric Qixing tea control group was significantly lower than that of the blank control group (P<0.01). On the 7th and 14th days, the food intake of the Qingqingle high, medium, low dose groups and the pediatric Qixing tea control group was significantly higher than that of the model group (P<0.01).

[0129] Table 8 Effects on body weight of young rats with food indigestion

[0130]

[0131] Note: Compared with the blank control group, *P<0.05, **P<0.01; compared with the model group, #P<0.05, ##P<0.01.

[0132] On the first day, the body weights of the model group, Qingqingle high, medium, low dose groups and the pediatric Qixing tea control group were significantly lower than those of the blank control group (P<0.05). On the 7th and 14th days, the body weights of the Qingqingle high, medium, low dose groups and the pediatric Qixing tea control group were significantly higher than those of the model group (P<0.05). Among them, on the 14th day, there was no significant difference in body weight between the Qingqingle high, medium, low dose groups and the blank control group and the pediatric Qixing tea control group.

[0133] Table 9 Effects on rectal temperature of young rats with food indigestion

[0134]

[0135] Note: Compared with the blank control group, *P<0.05, **P<0.01; compared with the model group, #P<0.05.

[0136] On the first day, the rectal temperatures of the model group, Qingqingle high, medium, low dose groups and the pediatric Qixing tea control group were significantly higher than those of the blank control group (P<0.05). On the 7th and 14th days, the rectal temperatures of the Qingqingle high, medium dose groups and the pediatric Qixing tea control group were significantly lower than those of the model group (P<0.05).

[0137] Table 10 Effects on gastric juice and serum protease activity in young rats with food indigestion

[0138]

[0139] Note: Compared with the blank control group, *P<0.05, **P<0.01; compared with the model group, #P<0.05.

[0140] Compared with the blank control group, the gastric juice volume, gastric juice pH value and pepsin activity in the model group were significantly reduced (P<0.01); compared with the model group, the gastric juice volume, gastric juice pH value and pepsin activity in the Qingqing Legao, medium dose group and Xiaoer Qixing Tea control group were significantly increased (P<0.05, P<0.01). The gastric juice volume and pepsin activity in the low dose group were significantly increased (P<0.05, P<0.01).

[0141] IV. Conclusion

[0142] The above experimental results show that Qingqingle extract at a dose of 6-24g / kg can effectively alleviate the indigestion reactions in rats, including weight loss, reduced food intake, increased rectal temperature, and decreased gastric juice volume, gastric acid pH, and pepsin activity, and is dose-dependent.

[0143] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit them; although the present invention has been described in detail with reference to the above embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the above embodiments, or replace some of the technical features therein by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A medicine-food combination, characterized in that: The invention is prepared from raw materials including malt, chrysanthemum, hawthorn, coix seed, yam, loquat leaf and liquorice.

2. The medicine-food homologous pharmaceutical composition according to claim 1, characterized in that: The invention comprises 60-100 parts by weight of malt, 20-60 parts by weight of chrysanthemum, 20-60 parts by weight of hawthorn, 20-60 parts by weight of coix seed, 5-45 parts by weight of yam, 20-60 parts by weight of loblolly leaf and 1-30 parts by weight of liquorice.

3. The medicine-food homologous pharmaceutical composition according to claim 1, characterized in that: Its preparation types include extracts, granules, tablets, capsules, powders or pills.

4. The method for preparing the edible-medicine-combination pharmaceutical composition according to any one of claims 1 to 3, characterized in that: It includes the following steps: (1) Take bamboo leaves, chrysanthemum, malt, liquorice, hawthorn, Chinese yam and coix seed, add them in the above order, add water to boil, filter, concentrate the combined filtrate for the first time, centrifuge, and concentrate the centrifuge for the second time to obtain a concentrated paste; (2) preparing fine powder auxiliary materials; (3) The concentrated paste is mixed with the fine powder auxiliary material, dried at 50-70° C., and granulated.

5. The preparation method according to claim 4, characterized in that: The step (2) comprises: grinding at least one carbohydrate auxiliary material to obtain fine powder and then passing it through a 80-120 mesh sieve.

6. The preparation method according to claim 4, characterized in that: The decoction is performed twice, with 8-12 times the amount of water added in the first decoction and 4-8 times the amount of water added in the second decoction. Each decoction takes 0.5-2 hours, and the decoctions are combined.

7. The preparation method according to claim 4, characterized in that: The first concentration is to a relative density of 1.02-1.05 at 55-60° C., and the second concentration is to a relative density of 1.28-1.

35.

8. The preparation method according to claim 4, characterized in that: The sugar auxiliary material includes white sugar and / or edible glucose, and after preparing the fine powder auxiliary material in step (2), the method further includes a step of mixing with prebiotics.

9. The preparation method according to claim 4, characterized in that: The feeding, extraction and concentration processes are carried out using an extraction tank, wherein the extraction tank includes an extraction liquid flow exchange device.

10. Use of the edible-medicinal composition according to any one of claims 1 to 3 in the preparation of a stomachic and digestive medicine or health food, characterized in that: The stomachic and digestive medicine or health food is used for preventing and / or improving food accumulation disorder in children.

Citation Information

Patent Citations

  • Preparation method of hawthorn wheat jujube chewable tablet

    CN109646607A

  • Medicine and food homologous food for removing pediatric excessive internal heat and preparation method thereof

    CN109999148A

  • Chrysanthemum and hawthorn composition

    CN111165623A

  • Multifunctional traditional Chinese medicine extraction tank

    CN111167159A